Overview


According to FutureWise analysis, the market for Sulfasalazine is expected to grow with a CAGR of 5.92% over the forecast period 2024-2032, and reach a market value of US$ 3.18 Billion by 2031. 

Sulfazine, also known by its generic name sulfasalazine, is a medication primarily used to treat (IBD) inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. It belongs to a class of drugs known as disease-modifying anti-rheumatic drugs (DMARDs) and is particularly effective in managing the symptoms associated with these conditions.

Sulfazine contains two active components, sulfapyridine and 5-aminosalicylic acid (5-ASA), which exert its therapeutic effects. Sulfapyridine is responsible for its anti-bacterial properties, while 5-ASA is the anti-inflammatory component. Together, they help to reduce inflammation and alleviate symptoms like abdominal pain, diarrhoea, and rectal bleeding commonly associated with IBD. The medication is typically administered orally, often in tablets or capsules. Sometimes, it may also be prescribed in liquid form for patients who find it difficult to swallow pills. Sulfazine is usually taken with food or after meals to help minimize stomach upset. Sulfazine may be associated with potential side effects. Common ones include gastrointestinal disturbances, such as nausea, loss of appetite, and mild stomach cramps. Additionally, some individuals may experience skin reactions or changes in urine or skin colour due to the medication. In some rare cases, more severe side effects may occur, such as liver problems or a decrease in blood cell count, requiring immediate medical attention.

FutureWise Market Research has published a report that provides an insightful analysis of Sulfasalazine Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Sulfasalazine Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Mylan N.V.
  • Reddy's Laboratories
  • Zydus Cadila
  • Sun Pharmaceutical Industries
  • Aspen Pharmacare
  • Apotex Inc.
  • Sandoz (a division of Novartis)
  • Lupin Limited

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Sulfasalazine Market:

  • In 2022, AbbVie introduced Apriso (sulfasalazine), a delayed-release capsule formulated to maintain steady drug levels throughout the day. It is available in a lower dose strength of 300 mg.
  • Similarly, Salix Pharmaceuticals released Salofalk Entabs (sulfasalazine) in 2021. This enteric-coated tablet is crafted for improved tolerance compared to conventional sulfasalazine tablets and is accessible in a lower dose strength of 500 mg.

The increasing incidence of conditions like ulcerative colitis, Crohn's disease, and inflammatory bowel syndrome (IBD), for which sulfasalazine is commonly prescribed, drives the demand for this medication. Sulfasalazine is known for its efficacy in reducing inflammation and alleviating symptoms associated with IBD, contributing to its demand. Sulfasalazine is a well-established medication readily available in various formulations, making it accessible to a broad patient population. Sulfasalazine is often considered a cost-effective treatment option compared to other medications for IBD, making it a preferable choice for patients and healthcare providers.

However, introducing newer, more targeted biological therapies and other advanced treatments for IBD may impact the demand for sulfasalazine and pose a challenge for the market growth.

Sulfasalazine may be associated with gastrointestinal discomfort and other side effects, leading to non-compliance or treatment discontinuation for some patients. While effective for many individuals, sulfasalazine may not provide adequate relief for all patients with IBD, necessitating alternative treatments. Sulfasalazine may interact with other medications a patient takes, limiting its use in individuals with complex medical conditions or those on multiple medications. Responses to sulfasalazine can vary from person to person. Not all patients may experience the same benefit level, leading to the need for personalized treatment plans and constraining the market.

By Product Type

  • Generic Sulfasalazine
  • Branded Sulfasalazine

By Application

  • Rheumatoid Arthritis
  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Ulcerative Colitis

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

By Patient Demographics

  • Adults
  • Pediatrics

By Disease Severity

  • Mild
  • Moderate
  • Severe

By Prescription Type

  • Over-the-Counter (OTC) with medical supervision
  • Prescription-only

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare

By Patient Education and Support

  • Patient Support Programs
  • Educational Material
  • Healthcare Professional Training

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the rising prevalence of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. In addition, the well-established healthcare infrastructure and high awareness about sulfasalazine in the region are also driving the market growth. Conversely, the European region is poised for substantial expansion in the forecast period due to the increasing prevalence of autoimmune diseases, the well-established healthcare infrastructure, and the high awareness of sulfasalazine.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Sulfasalazine Market By Product Type, By Application, By Distribution Channel, By Patient Demographics, By Disease Severity, By Prescription Type, By End User, By Patient Education and Support, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Sulfasalazine Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Sulfasalazine Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Sulfasalazine Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Sulfasalazine Market, By Product Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Generic Sulfasalazine
        2. Branded Sulfasalazine

  • 8.  Sulfasalazine Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Rheumatoid Arthritis
      2. Inflammatory Bowel Diseases
      3. Crohn's Disease
      4. Ulcerative Colitis
  • 9.  Sulfasalazine Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
      4. Specialty Clinics
  • 10.  Sulfasalazine Market, By Patient Demographics Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Adults
      2. Pediatrics
  • 11.  Sulfasalazine Market, By Disease Severity Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Mild
      2. Moderate
      3. Severe
  • 12.  Sulfasalazine Market, By Prescription Type Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Over-the-Counter (OTC) with medical supervision
      2. Prescription-only
  • 13.  Sulfasalazine Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
      4. Homecare
  • 14.  Sulfasalazine Market, By Patient Education and Support Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Patient Support Programs
      2. Educational Material
      3. Healthcare Professional Training
  • 15.  North America Sulfasalazine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 16.  Latin America Sulfasalazine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 17.  Europe Sulfasalazine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 18.  Asia Pacific Sulfasalazine Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 19.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 20.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 21.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc.
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Teva Pharmaceuticals
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Mylan N.V.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Reddy's Laboratories
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Zydus Cadila
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Sun Pharmaceutical Industries
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Aspen Pharmacare
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Apotex Inc.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Sandoz (a division of Novartis)
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Lupin Limited
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview

  • 22.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 23.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients